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ABSTRACT OF THESIS 
 
 
 
 
CALCITRIOL INCREASES CERAMIDE, DIACYLGLYCEROL AND EXPRESSION OF 
GENES INVOLVED IN LIPID PACKAGING IN SKELETAL MUSCLE CELLS 
 
Background: Vitamin D is crucial for skeletal muscle function.  25-hidroxyvitamin D 
(25(OH)D) has been correlated with skeletal muscle mass and intramyocellular lipid 
(IMCL) content. The purpose of this study was to understand how calcitriol, the 
active vitamin D metabolite, directly affects myocellular size and lipid partitioning. 
Methods: C2C12 myotubes were treated with calcitriol (100nM) or vehicle control for 
24 or 96 h. Myotube diameter and protein synthesis rate were measured to 
determine effects of calcitriol on myocellular size.  Intramyocellular triacylglycerol 
(IMTG), diacylglycerol (DAG), and ceramide content were measured by LC/MS.  
Expression of genes involved in lipid packaging and lipolysis were measured by RT-
PCR.  Insulin-stimulated phosphorylated Akt (Thr 308) was determined by western 
blot. 
Results:  Calcitriol did not affect myocellular size or protein synthesis rate.  Calcitriol 
increased total DAG and ceramides in a sub-species specific manner.  Calcitriol 
increased IMTG area, but did not affect total IMTG content.  Calcitriol reduced mRNA 
content of diglyceride acyltransferase and increased mRNA content of lipid 
packaging genes.  Calcitriol did not negatively affect insulin-stimulated pAkt. 
Conclusions: These results suggest calcitriol directly alters lipid content and 
packaging in skeletal muscle cells.  Altering the expression of lipid packaging genes 
and increasing IMCL subspecies content may be mechanisms by which vitamin D 
improves skeletal muscle function in vivo. 
KEYWORDS: (vitamin D, triacylglycerol, diacylglycerol, lipid packaging, muscle 
function)         
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INTRODUCTION  
Vitamin D has pleiotropic effects on health including increased muscle 
strength (25), improved physical function (73), and prevention of muscle atrophy 
(78).  Whole-body vitamin D status, as assessed by serum 25-hydroxyvitamin D3 
(25(OH)D), is positively associated with lean body mass (42).  Additionally, vitamin 
D supplementation has been shown to improve physical performance parameters 
(19, 25, 42, 73).  Furthermore, vitamin D appears to be essential for proper skeletal 
muscle function; vitamin D receptor knock out results in decreased grip strength 
and altered muscle fibers in mice (45).  Furthermore, vitamin D supplementation 
increases appendicular muscle strength (25), and reduces risk of falls in older 
individuals (10).   
Calcitriol (1,25(OH)2D3), the active form of vitamin D, directly regulates 
transcription of  more than 1,000 human genes (26, 91) via the Vitamin D Receptor 
(VDR).  It has recently been determined that the VDR is expressed within skeletal 
muscle (27, 48, 76), suggesting that vitamin D may directly impact skeletal muscle 
function.  However, the mechanism by which vitamin D improves skeletal muscle 
function has not been fully elucidated (46).  It has been hypothesized that vitamin D 
may enhance skeletal muscle function by increasing myocellular size (78).  Indeed, 
Girgis et al. (47) recently demonstrated that C2C12 myotubes treated with 100 nM 
25(OH)D and 100 nM 1,25(OH)2D for 7 or 10 days showed increased myotube 
diameter, suggesting vitamin D may improve muscular strength by inducing 
myocellular hypertrophy.  However, Van der Meijden et al. (62) recently reported 
that treating C2C12 myotubes with 100 nM calcitriol did not appreciably increase 
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myotube diameter or anabolic signaling through the Akt/mTOR pathway, suggesting 
that vitamin D does not increase myocellular protein synthesis.  Therefore, the 
direct effects of vitamin D on myocellular hypertrophy remain controversial.   
It has also been suggested that vitamin D may enhance skeletal muscle 
function and physical performance by altering intramyocellular lipid (IMCL) content 
(73).  Whole body vitamin D status is correlated with IMCL content in community-
dwelling older adults (73).  Calcitriol regulates phospholipid metabolism in skeletal 
muscle from rachitic chicks which has been proposed as a major mechanism by 
which calcitriol modulates muscle function (12).  Ryan et al. (75) showed low doses 
(10 nM) calcitriol directly increased lipid content of C2C12 myoblasts.  Together, 
these data suggest vitamin D increases IMCL content.   
In addition to increasing IMCL content, vitamin D may enhance muscle 
function by altering IMCL partitioning between triacylglycerols, diacylglycerols and 
ceramides.  Intramyocellular triglycerides (IMTG) constitute the majority of the lipid 
droplet within the muscle, and can serve as a readily available substrate for ATP 
production (4).  Additionally, IMTG content is associated with impaired force 
production (38) and insulin resistance (32, 60) in obese individuals.  However, 
endurance athletes display high amounts of IMTG, yet remain insulin sensitive (36), 
suggesting that IMTG content alone does not impair muscle function.   
IMTG are stored within the highly specialized lipid droplet organelle (4).  It 
has been postulated that the specific proteins covering the lipid droplet (collectively 
“coatamer” proteins) protect against the development of insulin resistance (15, 67, 
81, 96).  The perilipin (PLIN) family of proteins associate with the lipid droplet to 
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promote storage (PLIN 2,3) or lipolysis (PLIN5/Oxidative tissues enriched PAT 
protein (OXPAT)) of the constitutive lipids (67).  Overexpression of PLIN2 promotes 
increases in IMTG content (15) and improves insulin sensitivity in vitro (15).  
OXPAT overexpression promotes both IMTG accumulation and lipolysis in skeletal 
muscle (67, 97).  PLIN’s are thought to alter IMTG storage by enhancing (OXPAT) or 
repressing (PLIN 2,3) activity of the lipolytic enzymes, adipose triglyceride lipase 
(ATGL) and hormone sensitive lipase (HSL).  The direct effects of vitamin D on IMTG 
content and PLIN expression remain unclear.  
Two other lipid species, diacylglycerols (DAG), and ceramides, have recently 
been shown to serve as important regulators of skeletal muscle metabolic function 
(4, 22).  DAG are proposed to accumulate during incomplete lipolysis of IMTG (4) 
and can serve important roles in cell signaling by acting as a second messenger (4).  
Calcitriol has been shown to stimulate the biphasic formation of DAG in rat skeletal 
muscle (41).  Ceramides have been shown to modify intracellular signaling 
pathways to slow anabolism (9, 52).  Both DAG and ceramide content are closely 
associated with skeletal muscle and whole-body insulin resistance (3, 4, 22, 59).  It 
appears that DAG and ceramide affect cellular function in a sub-species dependent 
manner (4, 9, 52).  For example, fatty acid chain length appears to be a major 
determinant of ceramide function (9, 52).   
The purpose of this study was to determine the direct effects of calcitriol on 
myocellular size, IMCL partitioning between TAG, DAG, and ceramides, and lipid 
droplet packaging.  In order to eliminate indirect effects from other, vitamin D-
sensitive tissues, we employed a cell culture model (C2C12 myotubes) which has 
  4 
been used extensively to study skeletal muscle physiology (61, 66, 89).  Due to 
studies showing vitamin D supplementation improves myotube size (47, 62), we 
hypothesized that calcitriol increases myocellular size and protein synthesis.  
Additionally, due to data indicating vitamin D status is correlated with IMCL content 
and that calcitriol increases DAG and ceramide content in chick and rat skeletal 
muscle cells (13, 41), we hypothesized that calcitriol increases IMCL content, and 
modifies lipid partitioning and lipid droplet packaging in skeletal muscle.
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Literature Review  
 Skeletal muscle accounts for an estimated 35 - 42% of total body mass (46) 
and is essential for ambulation, respiration, and activities of daily living.  Low levels 
of skeletal muscle mass and strength are associated with increased risk of disability 
and death (29, 98).  Additionally, lipid content, composition, and fatty acid oxidation 
within skeletal muscle are highly associated with muscle function.  In obese 
individuals, intramyocellular triglyceride (IMTG) content is correlated with both 
impaired force production (8) and insulin resistance (60). Recently, diacylglycerol 
(DAG) and ceramides have been characterized as lipotoxic agents (4) and linked to 
development of insulin resistance both in vivo (1, 4) and in vitro (79).  
 Vitamin D therapy has pleiotropic health benefits including increased 
appendicular muscle strength and reduced risk of falls, mostly in older individuals 
with a low baseline vitamin D status (10, 69).  However, research examining the 
effects of vitamin D on skeletal muscle function is limited (46–48). Vitamin D status 
(serum 25(OH)D) is associated with lower incidence of injury (74) and higher levels 
of lean body mass (42), and muscle mass and strength (51).  Furthermore, Girgis et 
al. (47), have recently shown that 25(OH)D treatment increases myotube diameter, 
suggesting vitamin D may directly induce myocellular hypertrophy.  Therefore, 
vitamin D appears to enhance skeletal muscle function, potentially by inducing 
myocellular hypertrophy, which may contribute to improved health outcomes, such 
as decreased risk of falls (78), with vitamin D therapy. 
 Vitamin D is fundamental for proper contractile function of skeletal muscle.  
Curry et al. (34) showed that rabbits, rendered vitamin D deficient by dietary 
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methods, were substantially weaker than their vitamin D replete counterparts (34). 
Furthermore, vitamin D repletion restores physical function in vitamin D deficient 
humans (25, 49). Studies have found that aged human subjects receiving vitamin D 
therapy had a lower rate of falls (16, 49, 68). Additionally, Glerup et al. (49) 
demonstrated that, after vitamin D treatment, young Arab women displayed 
significant improvements in parameters of muscle function, including maximal 
voluntary contraction, knee and hip extensor muscle power, and single twitch 
contraction following 3 and 6 months of vitamin D repletion. Therefore, vitamin D 
therapy appears to improve whole-body and skeletal muscle function, but the 
cellular mechanisms behind this effect are unclear.  
Vitamin D Metabolism Overview 
Vitamin D3 (prohormone) is produced in the skin after exposure to sunlight 
and is hydroxylated in the liver to 25-hydroxyvitamin D3 (46).  In target tissues, 
25(OH)D3 is further hydroxylated to form calcitriol (1,25(OH)2D3), the active 
vitamin D metabolite, via 25-hidroxyvitamin D3 1-alpha-hydroxylase (encoded by 
the Cyp27b1 gene) (47, 76).  Traditionally, the major site of calcitriol formation has 
been thought to be the kidney (46).  However, recent data have shown Cyp27b1 
mRNA in other cell types, including adipocytes (62, 65) and skeletal muscle cells 
(62, 85).  However, the enzymatic activity of 25-hidroxyvitamin D3 1-alpha-
hydroxylase in these cells remains unknown.  Girgis et al. (47) recently 
demonstrated that cultured myotubes respond to 25(OH)D treatment, suggesting 
that these cells have the capacity to convert 25(OH)D to calcitriol. 
The cellular mechanism by which vitamin D improves muscle function has 
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not been fully elucidated.  In many tissues, calcitriol binds to the vitamin D receptor 
(VDR) to exert its biological effects (48, 68, 72), as described by Brumbaugh and 
Haussler (23).  The presence of the VDR has been reported in murine (47, 48), and 
human (24) muscle cells on the basis of immunohistochemistry (11, 24), 
equilibrium binding studies (83), and detection of VDR mRNA by RT-PCR (39).  
Recent evidence shows the VDR is expressed in human skeletal muscle (11, 28, 33). 
Calcitriol (1,25(OH)2D3) binds to this steroid receptor, which acts as a nuclear 
transcription factor (70).  Vitamin D restriction or VDR ablation significantly 
decreases muscle fiber cross-sectional area and grip strength in mice (45), 
suggesting signaling through the VDR is crucial for proper skeletal muscle 
contractile function.  Via the VDR, calcitriol has genomic effects to increase gene 
transcription which may directly affect muscle function and metabolism (33, 43).  
Specifically, 100 nmol/L calcitriol has been shown to increase mRNA content of 
myogenin (62) and several isoforms of myosin heavy chain (62) in cultured 
myotubes, indicating that calcitriol indeed alters gene transcription in skeletal 
muscle cells.   
Aside from the specific ability of the VDR to translocate from the cytosol to 
the nucleus in response to calcitriol, conformational changes of the flexible calcitriol 
molecule also determine the intermediation of genomic and non-genomic actions 
via its receptor (16, 24).  Alvarez et al. (3), summarized that vitamin D receptor gene 
polymorphisms and vitamin D interactions with the insulin like growth factor 
system may further influence glucose homeostasis, which could improve muscle 
function indirectly.  Additionally, treatment with calcitriol elicits rapid uptake of 
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calcium within muscle cells in vitro and in vivo (7, 35, 43), which is important for 
muscle contraction.  
Lipid Partitioning within Skeletal Muscle Cells  
 Whole-body vitamin D status as assessed by circulating serum 25-
hydroxyvitamin D3 (25(OH)D), has been associated with intramyocellular lipid 
(IMCL) content, or the total lipid content within skeletal muscle cells of elderly 
subjects (73).  Furthermore, calcitriol augments lipid accumulation within C2C12 
myoblasts (75), indicating that signaling through the vitamin D pathways may 
augment IMCL accretion. It has further been reported that vitamin D modifies 
phospholipids composition within in skeletal muscle which may impact skeletal 
muscle function (75).   
 Intramyocellular triacylglycerol (IMTG), which constitutes the majority of 
IMCL (4, 56), are packaged into lipid droplets (17, 96).  IMTG serves as a major 
substrate for oxidative metabolism, especially during low or moderate-intensity 
exercise (4).  However, in obese populations, accumulation of IMTG is associated 
with impaired force production (60) and insulin resistance (30).  Paradoxically, 
endurance-trained athletes have high levels of IMTG yet maintain contractile 
function and insulin sensitivity (4, 36).  In fact, Schrauwen et al. (80) showed that 
IMCL content is increased after only 2 weeks of aerobic training, indicating that 
accumulation of IMTG is an early adaptation to aerobic training.  This could be a 
beneficial adaptation considering IMTG is known as a substrate for oxidative 
metabolism during exercise.  Therefore, the role of IMTG in muscle dysfunction 
remains controversial.  
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 The lipid droplet is coated with a variety of proteins (collectively, “coatamer” 
proteins) that promote either storage (15), or lipolysis (97) of the constitutive 
IMTG.  Therefore, alterations in lipid droplet packaging may have direct effects on 
how IMTG affects myocellular function.  Perhaps the best-described coatamer 
proteins are the perilipin (PLIN) family.  PLIN 2-5 are expressed in skeletal muscle 
(96) and each isoform appears to uniquely affect lipid metabolism.   
PLIN2 and 3 are known to be necessary for lipid storage and expression of 
these proteins is increased in response to lipid overload (15).  Increased PLIN2 
expression has been associated with sarcopenia and muscle weakness (31).  
Furthermore, genetic knockdown of PLIN2 in C2C12 cells has been shown to increase 
cellular oxidative capacity (15).  Interestingly, PLIN2 overexpression has been 
shown to increase IMTG and ceramide content, and preserve insulin sensitivity in 
skeletal muscle (15).  In fact, PLIN2 (also known as adipophilin) has been proposed 
to protect against myocellular insulin resistance induced by various fatty acids (95).  
PLIN2 has been shown to increase co-localization with HSL on muscle lipid droplets 
with lipolytic stimulation (67, 71), suggesting PLIN2 may enhance lipolysis.  In 
support of this hypothesis, Shepherd et al. (82) found PLIN 2-associated IMTG was 
preferentially used during one hour of moderate-intensity endurance exercise (82).  
Furthermore, prolonged endurance-type training increased PLIN2 expression, with 
increases in IMTG content in diabetic patients (81).  This raises the possibility that 
lipid droplets coated with PLIN2 may be a favorable fuel substrate especially during 
exercise, which may protect against some of the lipotoxic effects of high lipid 
exposure/high fat diet. 
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 PLIN5 or the Oxidative tissues enriched PAT protein (OXPAT) is expressed in 
highly oxidative tissues and during states of increased fatty acid oxidation in 
skeletal muscle (17).  Many studies (67, 96, 97) have reported a correlation between 
skeletal muscle oxidative capacity and OXPAT content following endurance exercise, 
suggesting that OXPAT is involved in the regulation of fatty acid oxidation.  
Additionally, following endurance and sprint interval training, protein content of 
OXPAT increased in human vastus lateralis muscle (67) indicating that this protein 
responds to exercise stimuli.  Overexpression of OXPAT within skeletal muscle 
concomitantly increases expression of oxidative genes and IMTG content (15, 97).  
 Diacylglycerols (DAG) are lipid intermediates that accumulate within the cell 
during incomplete triacylglycerol hydrolysis.  Additionally, DAGs are generated by 
inositol triphosphate (IP3) cleavage from phosphatidylinositol 4,5-bisphosphate 
(PIP2) and thus, serve as secondary messengers of cell signaling (4, 93).  Excess DAG 
within skeletal muscle cells has been implicated in development of insulin 
resistance (58).  Endurance training has been shown to decrease DAG levels in 
human skeletal muscle (22, 36).  With this decrease in DAG, insulin sensitivity index 
was increased in obese human subjects post endurance training (22).  Interestingly, 
highly trained endurance athletes have been shown to have higher levels of DAG 
compared to sedentary or obese subjects (4), yet remain insulin sensitive.  These 
data suggest a more complex role for DAG in skeletal muscle.  Therefore, the role of 
DAG in skeletal muscle insulin resistance remains controversial.  Several recent 
papers have suggested ceramides, but not DAG, contribute to insulin resistance (1, 
79). 
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Calcitriol has been shown to influence myocellular DAG content.  Facchinetti 
et al. (41) found that in rat skeletal muscle, calcitriol stimulates the biphasic 
formation of DAG, and that the second phase of DAG formation was inhibited by the 
absence of extracellular calcium.  Calcitriol activated phospholipase D through a 
mechanism dependent on extracellular calcium and protein kinase C activation, but 
additional downstream effects of this mechanism, with all of its components remain 
unclear (41).   
 Ceramides, a type of bioactive sphingolipid typically found within the cell 
membrane, act as secondary messengers to inhibit anabolism and/or induce stress 
stimuli pathways (6, 9, 52).  Accumulation of ceramides has been associated with 
impaired metabolic function (4), specifically by inhibiting Akt (88, 100), a 
serine/threonine kinase that acts as an intermediate in the insulin signaling 
pathway (9).  Amati et al. (4), found that ceramide content was two-fold higher in 
muscle from obese, insulin-resistant subjects, compared to normal weight-
sedentary and endurance trained subjects.  These results are supported by previous 
studies that reported total ceramide is higher content in muscle of obese subjects 
(1) and is associated with insulin resistance and a lower oxidative capacity (30, 87).  
Vitamin D Increases Insulin Sensitivity 
Vitamin D supplementation has been shown to improve insulin sensitivity in 
obese and vitamin D-deficient humans (2, 54, 84).  Calcitriol has been shown to 
increase insulin-stimulated uptake of [3H]2-deoxyglucose in C2C12 myotubes 
following fatty-acid induced insulin resistance (101).  Therefore, calcitriol may 
directly improve skeletal muscle insulin sensitivity. 
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Conclusions 
Vitamin D is necessary for muscle function.  Since vitamin D repletion is 
known to improve muscle force and physical function parameters, it is likely that 
vitamin D directly increases myocellular size, which is a large determinant of force 
production.  However, research regarding the effects of vitamin D on myocellular 
size and protein synthesis remains equivocal (45, 47, 62).  Additionally, since 
calcitriol is associated with IMTG content and is known to increase DAG and 
ceramides, it is possible that calcitriol alters lipid partitioning, packaging, and 
utilization within skeletal muscle.  Calcitriol-induced modulation of myocellular size 
and/or lipid partitioning and packaging may have significant physiological 
ramifications for skeletal muscle function.   
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METHODS 
Cell Culture 
C2C12 (ATCC type) myoblasts were cultured in DMEM with 10% FBS, 
100IU/ml penicillin/-streptomycin and maintained at 37oC and 5% CO2.  Myoblasts 
were seeded at a density of 2.5 x 105 cells per well into six-well plates.  Once cells 
were 80% confluent, media was changed to low serum media (DMEM + 2% horse 
serum) to induce differentiation into myotubes.  Following terminal differentiation 
(~72-96 h), media was supplemented with non-esterified fatty acids (250μM 
palmitic acid and 250μM oleate) conjugated to BSA (Sigma Aldrich) to mimic 
circulating lipids in vivo.  These fatty acids were chosen because palmitic acid and 
oleate have been shown to be the most abundant lipid species found in human 
adipose tissue, circulating triacylglycerols, and circulating non-esterified fatty acids 
(53) and are usually the two most commonly consumed fatty acids (40).  
Additionally, myotubes were treated with calcitriol (100nM) or vehicle control 
(Ethanol).  This dosage of calcitriol has previously been shown to maximally activate 
VDR in C2C12 myotubes (43).  All experiments were conducted following either 24h 
or 96h exposure to fatty acids and calcitriol. 
Protein Synthesis and Content 
Protein synthesis rate was determined by measuring TCA precipitable 3H-
tyrosine incorporation as previously described (18).  Following 24h of calcitriol 
treatment, myotubes were incubated with 5 μCi/ml L-[3,5-3H] tyrosine 
(PerkinElmer Life Sciences) for 2h, washed thoroughly, and proteins precipitated 
with 10% TCA.  Proteins were scraped into microcentrifuge tubes, pelleted, and 
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solubilized in 0.2N NaOH.  Scintillation counting was performed and normalized to 
total protein content using a standard bicinchoninic acid (BCA) assay (Sigma 
Aldrich). 
Myotube Diameter and Oil Red O Measurements  
Following 24 and 96h of calcitriol treatment, images of myotubes were 
collected with an inverted microscope (Zeiss Observer D1) at a 40x magnification.  
Using Image J software (NCBI), individual myotubes were randomly selected and 
myocellular diameter was measured.  The mean of three measurements per 
myotube was reported to control for differences in diameter along the myotube axis.  
Six images were collected for each condition and 5 myotubes from each image were 
measured (30 myotubes per condition total).   
In order to determine the effects of calcitriol on IMTG content, Oil Red O 
staining was performed following 96 h of calcitriol treatment as previously 
described (36, 50).  Briefly, myotubes were washed with PBS, treated with 4% 
paraformaldehyde, and incubated in 60% Oil Red O for 10 minutes.  After washing 
residual Oil Red O from myotubes, images were collected using an inverted 
microscope (Zeiss Observer D1) at 40x magnification.  Using Image J software 
(NCBI), individual myotubes were randomly selected and myocellular area was 
measured.  These same myotubes were converted to threshold images, and the Oil 
Red O positive area was measured.  Oil Red O data were expressed as a percentage 
of total myotube area to control for differences in myocellular size.  Six images were 
collected from each condition and 5 myotubes from each image were measured (30 
myotubes per condition total). 
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Liquid chromatography – mass spectroscopy (LC/MS) 
Myocellular diacylglycerol and ceramide subspecies content were measured 
following 96 h of calcitriol treatment by liquid chromatography-mass spectroscopy 
(LC/MS) as previously described (44, 57).  Samples were delivered to the University 
of Kentucky Small Molecule Mass Spectrometry Laboratory core facility.  The 
specific DAG subspecies measured were 8:0, 10:0, 14:0, 16:0, 16:0-18:1, 18:0-18:2, 
18:0-20:4, 18:1, 18:1-20:0.  The specific ceramide subspecies measured were 14:0, 
16:0, 18:0, 20:0, 22:0, 24:0, and 24:1.  In order to determine whether alterations in 
ceramide content were due to changes in ceramide synthesis, dihydroceramide (DH-
cer) content was also measured.  The specific DH-cer subspecies measured were, 
16:0, 18:0, 20:0, 22:0, 24:0 and 24:1.  Since Oil Red O measures do not directly 
quantify amount of IMTG, we also analyzed content of 36 individual triacylglycerol 
sub-species by LC/MS.  To control for differences in myocellular seeding density 
and/or size, LC/MS data were normalized to total phospholipid content as 
previously described (55). 
Real-time PCR 
Following 24h of calcitriol treatment, total myocellular RNA was isolated by 
phenol-chloroform extraction and reverse transcribed to cDNA.  Quantitative RT-
PCR (ABI 7900, SYBRgreen chemistry) was performed using self-designed primers 
(NCBI algorithms) for genes involved in lipid droplet packaging (PLIN2, PLIN3, and 
OXPAT) and storage/lipolysis (CGI-58, ATGL, HSL, DGAT).  A list of primers used in 
the present study can be found in Table 1.  Primer specificity was confirmed by 
dissociation curve for all genes tested.  Relative gene expression was normalized to 
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the endogenous control gene Large Ribosomal Protein (RPLPO), which was 
unchanged by calcitriol treatment.  Relative gene expression was calculated using 
the ΔΔCt method. 
Immunoblots 
 
In order to determine how calcitriol affects myocellular insulin sensitivity, 
immunoblots were performed for total Akt (Cell signaling 9272) and 
phosphorylated Akt (Thr 308) (Cell signaling 5110) following insulin treatment.  
Myotubes were treated with calcitriol for 96 h and stimulated with 100 μM insulin 
for 15min.  Myotubes were washed twice with PBS and proteins collected in RIPA 
buffer with protease and phosphatase inhibitors (Sigma Aldrich).  Equal amounts of 
protein were separated by SDS-PAGE and transferred to nitrocellulose membranes.  
Membranes were incubated overnight in primary antibodies against pAkt and total 
Akt.  Specific bands were detected by enhanced chemiluminescence following 
treatment with HRP conjugated secondary antibodies.  Band density was measured 
using Image J software. 
Statistical Analysis 
All experiments were conducted with n = 3 and measurements made on at least two 
independent experiments with the exception of LC/MS.  Data are presented as mean 
± SE.  Statistical comparisons were made using t-test with α = 0.05, using GraphPad 
Prism 6 (version 6.05).  The exception was with myotube diameter and insulin 
stimulated pAkt where statistical comparisons were analyzed by two-way-ANOVA 
(Sidak post-test).  
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RESULTS 
100nM Calcitriol increases VDR gene expression.  
100nM calcitriol has previously been shown to maximally activate VDR 
transcription and activity in C2C12 myotubes (43, 85).  In order to confirm the 
effectiveness of this dosage, we treated C2C12 myotubes with 100nM calcitriol for 
24h and assessed mRNA content of VDR by RT-PCR.  As shown in Figure 1, VDR gene 
expression was significantly increased 4.66 fold after 24 h treatment with 100nM 
calcitriol. 
Calcitriol does not induce myocellular hypertrophy in vitro. 
It has previously been purported that vitamin D improves skeletal muscle 
mass and strength (25, 68, 72, 86).  In order to determine whether calcitriol directly 
increases myocellular size and protein synthesis, we measured protein synthesis, 
protein content, and myotube diameter and in C2C12 myotubes treated with calcitriol 
(100nM) or vehicle control for 24h or 96h.  Following 24 h, calcitriol treatment 
failed to increase myocellular protein synthesis rate (Figure 2A) or protein content 
(Figure 2B).  There was a significant main effect of time to increase myotube 
diameter.  Myotube diameter was significantly greater at 96 h compared to 24 h (p = 
0.0005).  However, myotube diameter was not significantly increased by calcitriol 
treatment at either 24 h or 96 h (Figure 2C).   
Calcitriol increases ceramide content in a subspecies-specific manner.  
Since vitamin D has been associated with IMCL content, we next wanted to 
determine how calcitriol affects partitioning of lipids between TAG, DAG, and 
ceramides.  In order to accomplish this, we treated C2C12 myotubes with 100 nM 
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calcitriol for 96 h and measured content of these lipid species by LC/MS.  As shown 
in Figure 3A, calcitriol increased total ceramide content by (1.22 fold, p = 0.019).  
Content of ceramides containing saturated fatty acids was not significantly altered 
by calcitriol treatment (Figure 3B).  However, content of ceramides containing 
unsaturated fatty acids was significantly increased (1.30 fold, p = 0.013) following 
96 h of calcitriol treatment (Figure 3C).  Examination of specific ceramide 
subspecies revealed the only ceramide subspecies that was significantly altered by 
calcitriol treatment was Cer-24:1, which was significantly increased (1.30 fold, p = 
0.026) (Figure 3D). 
Dihydroceramides (DH-cer) function as precursors for ceramide synthesis.  
In order to assess whether calcitriol alters myocellular ceramide synthesis, we also 
analyzed content of total DH-cer, as well as individual subspecies of DH-cer by 
LC/MS.  As shown in Figure 3E, total DH-cer content was increased (1.77 fold, p = 
0.006) by calcitriol treatment.  Interestingly, calcitriol significantly increased DH-cer 
24:0 (1.78 fold, p = 0.015) and DH-cer 22:0 (2.52 fold, p = 0.019) (Figure 3F).  
Calcitriol treatment increases myocellular diacylglycerol content. 
In order to determine how calcitriol directly affects myocellular DAG content, 
C2C12 myotubes were treated with 100nM calcitriol for 96 h and diacylglycerol 
content was measured by LC/MS.  As shown in Figure 4A, calcitriol significantly 
increased total DAG content (1.87 fold, p = 0.0002).  Calcitriol significantly increased 
content of saturated (2.17 fold, p = 0.0005) (Figure 4B), and mixed DAG, those 
containing one unsaturated and one saturated fatty acid (1.49 fold, p = 0.0002) 
(Figure 4C).  As shown in Figure 4D, calcitriol significantly increased several 
  19 
individual subspecies of DAG including di-14:0 (1.40 fold, p = 0.029), di-16:0 (1.31 
fold, p = 0.005), di-18:1 (1.69 fold, p = 0.0006), 16:0-18:1 (1.57 fold, p = 0.001), 
18:0-18:2 (1.38 fold, p = 0.0003), 18:0-20:4 (1.73 fold, p = 0.008), and 18:1-20:0 
(2.69 fold, p = 0.001).  Interestingly, the relative increase in di-18:0 (46.89 fold) in 
response to calcitriol was substantially greater than any other subspecies measured, 
suggesting that calcitriol preferentially increases expression of DAG containing di-
18:0 (Figure 4E). 
Calcitriol increases IMTG area but does not affect intramyocellular 
triacylglycerol content. 
We next wanted to assess IMTG content in response to calcitriol treatment.  
In order to accomplish this, we measured IMTG area (ORO) and TAG content 
(LC/MS).  Representative ORO images can be found in Figure 5A.  As shown in 
Figure 5B, 96 h of calcitriol treatment significantly increased the relative myotube 
ORO-positive area, indicating an increase in IMTG area.  Since ORO does not 
necessarily quantify IMTG content, we also analyzed content of 36 individual TAG by 
LC/MS.  As shown in Figure 5C, calcitriol did not significantly alter total TAG 
content. 
Calcitriol increases expression of genes involved in IMTG storage.  
In order to understand how calcitriol affects lipid droplet packaging, C2C12 
myotubes were treated with 100 nM calcitriol for 24 h and gene expression of PLIN 
2, PLIN 3, OXPAT, CGI-58, ATGL, HSL, and DGAT was analyzed via RT-PCR.  After 24 
h of calcitriol treatment, DGAT significantly decreased (0.22 fold, p = 0.04), with no 
significant change in CGI-58 (p = 0.12) or ATGL (p = 0.09) (Figure 6A).  Calcitriol 
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significantly increased both PLIN2 (2.13 fold, p = 0.008) and PLIN3 (1.55 fold, p = 
0.007) after 24 h (Figure 6B).  Conversely, calcitriol did not significantly alter OXPAT 
gene expression (1.52 fold, p = 0.16). 
Calcitriol induced changes in pAkt activity. 
 In order to determine how calcitriol affects myocellular insulin sensitivity, 
we performed immunoblots for total and phosphorylated (Thr 308) Akt.  
Representative immunoblots can be found in Figure 7A.  After calcitriol treatment 
for 96 h and 100μM insulin stimulation for 15 minutes, there was a trend (p = 
0.0591) toward increased pAkt in response to insulin, but it failed to reach 
statistical significance (Figure 7B).   
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DISCUSSION 
The major findings of the present study are: 1) calcitriol directly increases 
content of DAG and ceramide in a sub-species dependent manner and 2) calcitriol 
directly alters expression of genes involved in lipid droplet packaging.  Together, 
these data suggest a direct role of vitamin D in regulating lipid packaging and 
partitioning in skeletal muscle cells. 
Vitamin D has previously been associated with IMCL content in elderly adults 
(73).  Furthermore, calcitriol has been found to augment lipid accumulation within 
of C2C12 myoblasts (75).  Together, these data suggest that vitamin D may augment 
IMCL accretion.  Historically, higher levels of TAGs, DAGs and ceramides have been 
associated with insulin resistance (30, 37).  However, in the present study, calcitriol 
did not negatively affect insulin stimulated pAkt.   
In our study, we discovered that calcitriol treatment increased expression of 
the PLIN “coatamer” or lipid packaging proteins, and decreased DGAT, which is 
directly involved in triglyceride synthesis.  Calcitriol did not alter expression of 
genes involved in triglyceride lipolysis.  Shepherd et al. (82), found that PLIN2-
containing lipid droplets were preferentially used during one hour of moderate-
intensity cycling suggesting that increased PLIN2 expression may increase the 
ability of these lipid droplets to undergo lipolysis.  Therefore, calcitriol-induced 
increases in PLIN2 and PLIN3 may serve to enhance lipolysis and lipid oxidation. 
In the present study calcitriol increased total, saturated and mixed DAG.  
Myocellular DAG have previously been associated with lipotoxicity and insulin 
resistance (6, 59).  However, Amati et al. (4) demonstrated that, compared to 
  22 
sedentary individuals, total and mixed DAG content is higher in endurance-trained 
athletes.  Specifically, these athletes displayed exceptionally high levels of di-18:0 
DAG.  Interestingly, in the present study, calcitriol preferentially increased content 
of DAG containing di-18:0.  Myocellular DAG are often thought to arise from 
incomplete hydrolysis of IMTG (4).  However, it is well established that DAG serve 
important roles as secondary messengers in cell signaling (4).  Morelli et al. (64) 
showed that calcitriol increases DAG in chick-embryo muscle cells concomitant with 
increases in inositol trisphosphate, suggesting that rapid increases in DAG may be 
due to increases phospholipase C activity rather than incomplete IMTG hydrolysis.  
Accumulation of DAG via this mechanism rather than incomplete IMTG hydrolysis 
may explain the apparent paradox between concomitant increases in insulin 
responsiveness and DAG content seen in the present study.  Alterations in 
myocellular lipid composition has been purported to be a major avenue of vitamin 
D-induced improvements in muscle function (46).  It is possible that increases in 
DAG, especially, those containing di-18:0, may be one mechanism by which calcitriol 
improves skeletal muscle metabolic function. 
In the present study, calcitriol directly increased ceramide content.  
Ceramides act as secondary messengers in many signaling pathways (6, 9, 52), but 
their accumulation in muscle has also been associated with impaired insulin 
resistance (4).  In addition to Adams et al. (1) which reported a higher total 
ceramide content in obese muscle, Amati et al. (4), found that ceramide content was 
also two-fold higher in insulin-resistant muscle from obese subjects, in comparison 
to muscle from normal weight-sedentary and endurance trained subjects.  A major 
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mechanism through which ceramide alters cellular metabolism is inhibition of Akt 
(88, 100), a serine/threonine kinase that acts as an intermediate in the insulin 
signaling pathway (9).  Grosch et al. (52) summarized that ceramides have been 
shown to have specific chain-length dependent properties, such as short chain 
dihydroceramides being associated with autophagy (99) and long chain ceramides 
being associated with apoptosis (92).  Interestingly, in the present study, calcitriol 
only significantly increased content of Cer-24:1.  Argraves et al. (5) found an inverse 
relationship between Cer-24:1 in serum HDL and ischemic heart disease and noted 
that it may contribute to the protective role of HDL in the disease process (5).  It is 
possible that, unlike other ceramide sub-species, specifically increasing Cer-24:1 
may improve muscle metabolic function.  Although several papers have measured 
ceramide sub-species content (4, 5, 20, 44), few, if any, have shown a direct link 
between individual sub-species and insulin resistance.  Future research should be 
aimed at determining whether alterations in specific lipid sub-species such as di-
18:0 DAG and Cer-24:1 mediate the positive effects of vitamin D on skeletal muscle 
performance in vivo. 
It has been previously reported that vitamin D inhibits free fatty acid-induced 
insulin resistance in skeletal muscle cells (101).  IMTG, DAG and ceramide have all 
been implicated as potential causes of myocellular insulin resistance (59, 94).  
Therefore, due to the substantial increase in DAG and ceramide in the present study, 
we wanted to examine how calcitriol affects insulin sensitivity.  We found that 
calcitriol treatment preserved insulin-stimulated Akt phosphorylation at Thr 308 
suggesting that calcitriol maintains insulin sensitivity despite increases in 
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myocellular DAG and ceramide.  The specific mechanism(s) underlying calcitriol-
induced insulin sensitivity warrant further investigation. 
Figure 8 presents a potential mechanism for how calcitriol regulates lipid 
partitioning/packaging, and insulin resistance.  In our model, calcitriol induces 
translocation of the VDR to the nucleus, which increases transcription of PLIN2 and 
PLIN3 to increase lipid droplet surface area and increase insulin sensitivity.  Since 
our data show calcitriol increases PLIN2 and PLIN3, but does not alter IMTG 
content, we postulate that calcitriol increases myocellular lipid droplet number.  
Previous reports have shown that exercise-induced increases in IMTG content are 
due to increased lipid droplet number, but not size (90).  Since this effect occurs 
concomitantly with increased fatty acid oxidation, it appears that maximizing lipid 
droplet surface area may increase myocellular lipolytic potential, limiting any 
lipotoxic effects of IMTG accumulation.  PLIN2 knockdown increases lipid droplet 
size in an attempt to maximize the volume-to-surface ratio in the available lipid 
droplets (15).  Therefore, it appears PLIN2 may limit lipid size, and maximize 
surface area of lipid droplets.  Maximizing lipid droplet surface area may provide 
additional opportunities for lipolytic enzymes to mobilize fatty acids from 
constituent IMTG, thus limiting potential lipotoxic effects of IMTG.     
Most (1, 4, 37, 59, 87), but not all (21), studies have shown increased 
myocellular ceramide content is associated with insulin resistance.  Brown et al. 
(21) demonstrated that increased ceramide levels in the liver did not impair insulin 
sensitivity, suggesting that ceramide subspecies composition, rather than total 
ceramide content, may be a more important determinant lipotoxicity.  Additionally, 
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Bosma et al. (15), found that PLIN2 overexpression rescued palmitate-induced 
insulin resistance, despite increased IMTG and total ceramide content within 
skeletal muscle.  These researchers did not report changes in specific ceramide 
subspecies.  Therefore, the direct effects of PLIN2 on specific ceramide subspecies 
remain unknown.  However, it is possible that PLIN2 increases ceramide content in 
a subspecies dependent manner. 
Previous studies have shown vitamin D status is highly related to physical 
function (25, 73).  Furthermore, calcitriol therapy (77) and supplementation (78) 
increases skeletal muscle strength, which has been suggested to be due to 
myocellular hypertrophy (14, 47).  Girgis et al. (45) found that VDR knockout and 
vitamin D-deficient mice had significantly weaker hand grip strength and increased 
myostatin levels in the quadriceps muscle, which could promote protein 
degradation and muscle atrophy.  Therefore, we wanted to determine how calcitriol 
affects myocellular size.  With our calcitriol treatment (100 nM), we found no 
change in myotube diameter, protein content, or protein synthesis rate.  These data 
support the findings of Van der Meijden et al. (62) who showed calcitriol had no 
effect on protein synthetic signaling (pAkt, pP70/pS6) in C2C12 myoblasts.  These 
data indicate that calcitriol does not directly increase myocellular size.  However, 
calcitriol could be mediating its effects indirectly to cause hypertrophy.  Garcia et al. 
(43) demonstrated that the addition of calcitriol to C2C12 myoblasts increased 
fibroblast growth factor 1 (FGF-1) which promotes vascularization and tissue 
regeneration, while it decreased fibroblast growth factor 2 (FGF-2), a myogenic 
inhibitor.  It should be mentioned that our findings conflict with those of Girgis et al. 
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(47) who showed that 10 d of 100 nM calcitriol treatment increased diameter of 
C2C12 myotubes.  Although calcitriol is considered the active vitamin D metabolite, it 
is possible that the length of calcitriol treatment explains our disparate results (47).  
Our treatment was terminated at 96h, at which point we observed a small, 
nonsignificant trend (1.09 fold, p = 0.0578) for calcitriol to increase myotube 
diameter.  It is possible that with a longer duration of calcitriol treatment, we may 
have observed an increase in myotube hypertrophy.  These results suggest a dosage 
and duration specific effect of calcitriol on myocellular size.  To our knowledge, this 
is the first study to examine the effects of calcitriol on protein synthesis rate in 
differentiated myotubes. 
Vitamin D has long been known to be essential for optimal skeletal muscle 
function (14, 46, 47, 49, 68).  Our results indicate that calcitriol directly alters 
expression of genes involved in lipid droplet packaging and increases content of 
DAG and ceramide in a sub-species dependent manner.  However, we found no 
direct effect of calcitriol on myocellular size or protein synthesis in vitro.  It is 
possible that alterations in lipid droplet packaging and lipid subspecies content may 
be involved in vitamin D-induced improvements in skeletal muscle function.  
Further research is needed to determine the precise role of calcitriol-induced 
alterations in lipid partitioning and packaging in skeletal muscle metabolism.
  27 
 
Gene  Sequence (5’-3’) 
VDR 
F CCACCACAAGACCTACGACC 
R ATCATGTCCAGTGAGGGGGT 
CGI-58 
F CGGTGGAGGGTCAGGATGG 
R TATGCGCACAGGCTCTTTCT 
ATGL 
F GAGGAATGGCCTACTGAACC 
R AGGCTGCAATTGATCCTCCT 
HSL 
F CCTGGCAGTGGTGTGTAACTA 
R AGAACGCTGAGGCTTTGATCTT 
DGAT 
F AAGAGGACGAGGTGCGAGAC 
R GATGGCACCTCAGATCCCAGTA 
PLIN 2 
F TCAGCTCTCCTGTTAGGCGT 
R TTCTCGGCCATCTCACACAC 
PLIN 3 
F ATGAACACTCCCTCGGCAAG 
R CCTGTGGGGTCTTCTGGTTC 
OXPAT 
F TACTTTGTGCGTCTGGGGTC 
R CTGGGTACGGTGTTTGCTCT 
RPLPO 
F ACCCTGAAGTGCTCGACATC 
R CCGATCTGCAGACACACACT 
Table 1.  List of real-time polymerase chain reaction (RT-PCR) primers.  VDR = 
vitamin D receptor.  CGI-58 = comparative gene identification – 58.  ATGL = adipose 
triglyceride lipase.  HSL = hormone sensitive lipase.  DGAT = diglyceride 
acyltransferase.  PLIN 2 = perilipin 2.  PLIN 3 = perilipin 3.  OXPAT = oxidative 
tissues enriched PAT protein.  RPLPO = large ribosomal protein. 
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Figure 1.  100 nM calcitriol increases gene expression of the Vitamin D 
Receptor.  C2C12 myotubes were treated with calcitriol (100 nM) or vehicle control 
for 24 h and VDR gene expression was measured by RT-PCR.  Data are expressed as 
mean ± SE (n=3 per group).  *p < 0.05.  VDR = Vitamin D Receptor.  Veh = vehicle 
treated.  Cal = 100 nM calcitriol. 
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Figure 2.  Calcitriol does not directly induce myocellular hypertrophy.  C2C12 
myotubes were treated with calcitriol (100 nM) or vehicle control for 24 or 96 h. (A) 
24 h of calcitriol treatment did not alter myocellular protein synthesis (3H-tyrosine 
incorporation).  (B) Protein content was unchanged by calcitriol treatment after 24 
h.  (C) Myotube diameter was unchanged by calcitriol treatment after 24 or 96 h.  
Data are expressed as mean ± SE (n=3 per group).  * p < 0.05 compared to 24 h.  Veh 
= vehicle treated.  Cal = 100 nM calcitriol. 
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Figure 3.  Calcitriol increases total ceramide content, specifically ceramide 
24:1.  C2C12 myotubes were treated with calcitriol (100 nM) or vehicle control for 96 
h and ceramide content measured by LC/MS.  (A) Total ceramide content was 
increased by calcitriol treatment after 96 h.  (B) Saturated fatty acid ceramide 
content was unchanged by calcitriol treatment after 96 h.  (C) Unsaturated fatty acid 
ceramide content was increased after calcitriol treatment for 96 h.  (D) Ceramide 
24:1, was exclusively increased by calcitriol treatment after 96 h.  (E) 
Dihydroceramides, normalized to total phospholipid content, increased with 
calcitriol treatment after 96 h.  (F) Total dihydroceramide content fold change, 
specifically DH-Cer 24:0, increased after 96 h of calcitriol treatment.  Data are 
expressed as mean ± SE (n=3 per group) and normalized to total phospholipid 
content.  * p < 0.05.  Veh = vehicle treated.  Cal = 100 nM calcitriol.  Cer = ceramide.  
DHCer = dihydroceramide.  
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Figure 4.  Calcitriol increases total, saturated, and mixed diacylglycerol (DAG) 
content and certain DAG subspecies.  C2C12 myotubes were treated with calcitriol 
(100 nM) or vehicle control for 96 h and DAG content measured by LC/MS.  (A) 
Total DAG content was increased by calcitriol treatment after 96 h.  (B) Saturated 
DAG content was increased by calcitriol treatment after 96 h.  (C) Mixed DAG was 
increased after calcitriol treatment for 96 h.  (D) DAG content of specific subspecies 
was increased by calcitriol treatment after 96 h.  (E) DAG 18:0 increased with 
calcitriol treatment after 96 h.  Data are expressed as mean ± SE (n=3 per group).  * 
p < 0.05.  Veh = vehicle treated.  Cal = 100 nM calcitriol.  DAG=diacylglycerol.  
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Figure 5.  Calcitriol increases intramuscular triacylglycerol area, but not 
content.  C2C12 myotubes were treated with calcitriol (100 nM) or vehicle control 
for 96 h, and IMTG content assessed by Oil Red O staining and LC/MS.  (A) 
Representative Oil Red O (ORO) staining with vehicle or calcitriol treatment.  (B) 
IMTG area (% covered by ORO) increased with calcitriol treatment after 96 h.  (C) 
Total TAG content was unchanged by 96 h of calcitriol treatment.  Data are 
expressed as mean ± SE of each group (n=3 per group).  * p < 0.05.  Veh = vehicle 
treated.  Cal = 100 nM calcitriol.  IMTG = intramuscular triacylglycerol.  TAG = 
triacylglycerol.  
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Figure 6.  Calcitriol decreases DGAT gene expression and increases PLIN 2 and 
PLIN3 gene expression.  C2C12 myotubes were treated with calcitriol (100 nM) or 
vehicle control for 96 h and analyzed by real time polymerase chain reaction (RT-
PCR) analysis.  (A) DGAT gene expression decreased after 96 h calcitriol and lipid 
treatment.  (B) Calcitriol increased PLIN2 and PLIN3 gene expression, while OXPAT 
was unchanged after 96 h.  Data are expressed as mean ± SE of each group (n=3 per 
group).  * p < 0.05 vs. Veh.  Veh = vehicle treated.  Cal = 100 nM calcitriol.  CGI-58 = 
comparative gene identification-58.  ATGL = adipose triglyceride lipase.  HSL = 
hormone sensitive lipase.  DGAT = diglyceride acyltransferase.  PLIN = perilipin.  
OXPAT = oxidative tissues enriched PAT protein. 
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Figure 7.  Calcitriol maintains insulin sensitivity during high fat exposure.  
C2C12 myotubes were treated with a calcitriol (100 nM) or vehicle control with 
100μM insulin stimulation for 15 minutes and measured by immunoblots.  (A) 
Representative immunoblot.  (B) pAkt normalized to tAkt content increased after 
calcitriol treatment for 96 h and insulin treatment for 15 minutes, but only in 
response to calcitriol.  Data are expressed as mean ± SE of each group (n=3 per 
group).  * p < 0.05 vs. Basal.  Veh = vehicle treated.  Cal = 100 nM calcitriol.  pAkt = 
phosphorylated protein kinase B.  tAkt = total protein kinase B.  
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Figure 8.  Potential mechanism to explain calcitriol-induced alterations in 
myocellular lipid content and packaging.  Calcitriol increases transcription of 
lipid packaging genes, specifically PLIN2 and PLIN3, directly by the vitamin D 
receptor (VDR).  PLIN2 and 3 increase lipid droplet surface area (but not IMTG 
content), ceramide 24:1 content, and preserve insulin sensitivity by increasing 
lipolytic flux.  VDR = vitamin D receptor.  PLIN = perilipin.
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